within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK10_VilanterolAndFluticasoneFuroate;

model VilanterolAndFluticasoneFuroate
  extends Pharmacolibrary.Drugs.ATC.R.R03AK10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AK10</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vilanterol and fluticasone furoate is a combination inhaled medication used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Vilanterol is a long-acting beta2-adrenergic agonist (LABA), while fluticasone furoate is an inhaled corticosteroid. The drug is approved and regularly used in clinical practice for long-term management of airway obstruction.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from published studies in healthy adult subjects for inhaled administration of vilanterol 25 mcg and fluticasone furoate 100 mcg once daily.</p><h4>References</h4><ol><li><p>Chen, X, et al., &amp; Allen, A (2015). Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. <i>Pharmacotherapy</i> 35(6) 586–599. DOI:<a href=&quot;https://doi.org/10.1002/phar.1598&quot;>10.1002/phar.1598</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26059225/&quot;>https://pubmed.ncbi.nlm.nih.gov/26059225</a></p></li><li><p>Li, Y, et al., &amp; Ma, P (2019). Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. <i>Clinical pharmacology in drug development</i> 8(6) 721–733. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.626&quot;>10.1002/cpdd.626</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30427594/&quot;>https://pubmed.ncbi.nlm.nih.gov/30427594</a></p></li><li><p>Siederer, S, et al., &amp; Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. <i>European journal of drug metabolism and pharmacokinetics</i> 41(6) 743–758. DOI:<a href=&quot;https://doi.org/10.1007/s13318-015-0303-4&quot;>10.1007/s13318-015-0303-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26474864/&quot;>https://pubmed.ncbi.nlm.nih.gov/26474864</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end VilanterolAndFluticasoneFuroate;
